• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press
VASRO GmbH

Microsoft’s Workforce Strategies Shaping 2025 Trends

  • January 13, 2025
  • Tech
Microsoft confirms performance-based job cuts across departments, focusing on AI, security, and innovation to align workforce strategies with 2025 trends.
Continue Reading
VASRO GmbH

Why Nvidia’s Jensen Huang’s quantum computer claims matter in 2025

  • January 10, 2025
  • Tech
Nvidia’s Jensen Huang is ‘dead wrong’ about quantum computers, sparking debate over his 15-30 year timeline and its impact on Nvidia and the tech sector.
Continue Reading
VASRO GmbH

How Uber and Lyft Are Preparing for the Robotaxi Revolution in 2025

  • January 9, 2025
  • Tech
How Uber and Lyft are gearing up for the robotaxi revolution with partnerships, app updates, and infrastructure to deploy autonomous fleets by 2025.
Continue Reading
VASRO GmbH

Pharma share analysis 2025 Current trends and developments

  • January 8, 2025
  • Pharma & Biotech
Pharma share analysis 2025: Discover trends such as mRNA technology, biotechnology and AI. Opportunities, risks and forecasts for investors at a glance.
Continue Reading

Microsoft’s $80 Billion AI Investment Reshaping the Tech Industry

  • January 7, 2025
  • Tech
Microsoft expects to spend $80 billion on AI-enabled data centers in fiscal 2025, reshaping the tech industry with innovation, infrastructure, and global impact.
Continue Reading

Big Pharma Layoffs Surge in 2024: What It Means for the Industry

  • January 6, 2025
  • Pharma & Biotech
Big Pharma layoff rounds jump in '24, with 25,000 jobs cut. Explore the reasons, impacts on innovation, and patient care challenges in the industry.
Continue Reading

FDA Approves Subcutaneous Version of Bristol Myers’ Opdivo: What It Means

  • January 2, 2025
  • Pharma & Biotech
FDA approves subcutaneous version of Bristol Myers' Opdivo, Opdivo Qvantig, offering faster, patient-friendly cancer care and boosting oncology innovation.
Continue Reading

Why ESG Matters for Tech and Pharma Investments

  • January 2, 2025
  • Pharma & Biotech
The role of ESG in tech and pharma investments drives innovation, mitigates risks, and ensures long-term value by addressing environmental, social, and governance challenges.
Continue Reading

Fujirebio and Eisai Join Forces to Revolutionize Neurodegenerative Diagnostics

  • December 26, 2024
  • Pharma & Biotech
Fujirebio and Eisai partner to advance diagnostics for neurodegenerative diseases, focusing on blood-based biomarkers for early detection and improved care.
Continue Reading

The Most Exciting Tech Developments in Silicon Valley for 2025

  • December 26, 2024
  • Tech
Silicon Valley's latest innovations for 2024 and 2025, including AI, blockchain, and quantum computing, are set to transform industries and redefine technology.
Continue Reading

Posts pagination

Previous 1 … 28 29 30 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.